AstraZeneca has entered into drug price negotiations with the National Health Insurance Service for its ‘Fasenra Prefilled Syringe Inj (benralizumab, AZ),’ a severe eosinophilic asthma treatment that passed the Health Insurance Review and Assessment Service's Drug Reimbursement Evaluation Committee review in March.

With other drugs with the same mechanism of action such as Cinqair and Nucala already listed for reimbursement in Korea, whether Fasenra will also be granted reimbursement in Korea is gaining attention.

According to an industry source on the 16th, the National Health Insurance Service is in drug price negotiations with AstraZeneca for Fasenra.

In particular,